Symbiosis Pharmaceutical Services say the company has completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland. The fully integrated sterile liquid fill/finish system operates under a Grade A Restricted Access Barrier System (RABS).
Designed to deliver with both precision and efficiency, it incorporates rapid transfer ports for aseptic handling and high-accuracy vial filling with flexicon pump technology, notes Colin MacKay, CEO, who adds that the system also features a rotary crimp mechanism to ensure consistent overseal application and secure closure.
“The qualification of our automated fill/finish line…enhances our technical capabilities and expands our capacity at a time when demand for high-quality sterile manufacturing continues to grow. Most importantly, it strengthens our ability to help clients bring vital therapies to patients quickly and to the highest regulatory standards,” says MacKay.
Symbiosis expects to begin commercial production at their new facility in Q4 2025, manufacturing batches of up to 15,000 vials.
